Table 3. Sensitivity, specificity and predictive values of different HBsAg levels for predicting insignificant fibrosis among patients with ALT ≤2×ULN (n = 56).
| HBsAg (IU/mL) | Number of patients | Sensitivity | Specificity | PPV | NPV | LR+ | LR− |
| ≥10,000 | 45 | 90.9% | 58.3% | 88.9% | 63.6% | 2.18 | 0.16 |
| ≥25,000 | 41 | 86.4% | 75.0% | 92.7% | 60.0% | 3.46 | 0.18 |
| ≥50,000 | 32 | 68.2% | 83.3% | 93.8% | 41.7% | 4.08 | 0.38 |
| ≥75,000 | 24 | 52.3% | 91.7% | 95.8% | 34.4% | 6.30 | 0.52 |
| ≥100,000 | 16 | 36.4% | 100% | 100% | 30.0% | – | 0.64 |
Insignificant fibrosis defined as Ishak fibrosis score ≤1.
HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; ULN, upper limit of normal; PPV, positive predictive value; NPV, negative predictive value, LR+, positive likelihood ratio; LR-, negative likelihood ratio.